in vitro News and Research

RSS

$6.4 million awarded to investigate mechanisms of allergy tolerance generated by Circassia’s ToleroMune Treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the United States’ National Institutes of Health (NIH) has awarded a $6.4 million grant to Professor Mark Larché of McMaster University, Canada, to study mechanisms of tolerance developed by patients treated with Circassia’s Toleromune® allergy therapy.

7 Jun 2012

Studies evaluate transplantation potential and success of islet cells derived from pancreatic tissues

Two studies appearing in the current issue of Cell Transplantation, evaluate the transplantation potential and success of islet cells derived from pancreatic tissues, in addition to a clinical study that reports the occurrence of adverse events.

7 Jun 2012

CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing

The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue of Cancer Research.

7 Jun 2012

Ancient berry could protect against diabetic retinopathy

The ancient Tibetan goji berry could help fight blindness caused by long-term diabetes according to studies conducted by University of Sydney researchers.

5 Jun 2012

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Researchers at Universitat Aut-noma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the --amyloid protein, involved in Alzheimer's disease.

5 Jun 2012

Patients with normal lipoprotein(a) levels may retain risk of atherosclerosis due to elevated LDL-P number

LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced results from a clinical study demonstrating that patients with normal levels of lipoprotein(a) may retain significant risk of atherosclerosis due to an elevated low density lipoprotein particle (LDL-P) number.

2 Jun 2012

Researchers identify chromosomal make-up of human eggs

In a groundbreaking study, Yale School of Medicine researchers and colleagues at the University of Oxford have identified the chromosomal make-up of a human egg. This discovery may soon allow them to avoid using abnormal - or aneuploid - eggs during infertility treatments, and instead to pick eggs that are healthy enough for a successful in vitro fertilization (IVF) cycle.

2 Jun 2012

IPD connector outperforms negative pressure, split-septum needleless IV connector

InVision-Plus with Neutral Advantage Technology outperformed a negative pressure, split-septum needleless IV connector in a prospective study that examined the association of different IV connector types with catheter-related bloodstream infection (CR-BSI) rates.

2 Jun 2012

Precision Therapeutics’ ChemoFx test feasible in cervical cancer

Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

2 Jun 2012

Amarantus to announce results from preclinical study of new protein therapy for TBI

Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., announced today that its latest joint venture target, Amarantus BioSciences, Inc., expects to announce the results of a preclinical study evaluating the potential of its new protein therapy as a treatment for Traumatic Brain Injury (TBI).

2 Jun 2012

JMC publishes results from Rexahn’s RX-3117 preclinical cancer study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Journal of Medicinal Chemistry on the anti-tumor activity of its RX-3117 compound.

1 Jun 2012

Ventana, leading cancer researchers partner to commercialize novel IHC primary antibody

Ventana Medical Systems, Inc., a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein.

1 Jun 2012

New photoactive compound eradicates 'Iraqibacter' from wounds and skin infections

Researchers at the University of California, Santa Cruz, have developed a novel approach for eradicating drug-resistant bacteria from wounds and skin infections, using light to trigger the controlled release of nitric oxide. The UCSC team developed a photoactive compound that releases nitric oxide when exposed to light, and loaded it into a porous, biocompatible material that could be applied as a sprayable powder.

31 May 2012

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.

30 May 2012

Lung in Oncology models for drug discovery launched by PRECOS

Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, has launched its Lung In ONcology model atlas (LION).

29 May 2012

Fluxion Biosciences announces launch of Discovery Services business

Fluxion Biosciences, a privately held drug discovery tools and services company, announced today that it is launching a Discovery Services business to support growing demand for assay support on Fluxion's unique cell analysis platforms.

From Fluxion Biosciences 29 May 2012

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced the initiation of patient enrollment in a Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb in healthy volunteers.

29 May 2012

AngioPredict project to focus on patients with metastatic colorectal cancer

The Royal College of Surgeons in Ireland (RCSI) is leading an international team of scientists on a major research study which aims to predict colorectal cancer patients' response to the 'angiogenesis inhibitor' class of anti-cancer drug which prevents growth of tumour blood vessels. The study will facilitate a more focused therapeutic approach thus limiting side-effects in patients.

28 May 2012

ABL receives CE-IVD approval for DeepChek and ViroScore Suite clinical genotyping solutions

Advanced Biological Laboratories (ABL) announced today that DeepChek and ViroScore Suite clinical genotyping solutions are now CE-IVD (In Vitro Diagnostics) approved for commercial use in Europe and other countries that recognise CE certification.

28 May 2012

Cepheid’s Xpert CT/NG system receives European CE marking

Cepheid today announced that both Xpert CT/NG and Xpert CT have received CE marking, with shipments expected to begin immediately.

24 May 2012

in vitro News and Research

$6.4 million awarded to investigate mechanisms of allergy tolerance generated by Circassia’s ToleroMune Treatment

Studies evaluate transplantation potential and success of islet cells derived from pancreatic tissues

CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing

Ancient berry could protect against diabetic retinopathy

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Patients with normal lipoprotein(a) levels may retain risk of atherosclerosis due to elevated LDL-P number

Researchers identify chromosomal make-up of human eggs

IPD connector outperforms negative pressure, split-septum needleless IV connector

Precision Therapeutics’ ChemoFx test feasible in cervical cancer

Amarantus to announce results from preclinical study of new protein therapy for TBI

JMC publishes results from Rexahn’s RX-3117 preclinical cancer study

Ventana, leading cancer researchers partner to commercialize novel IHC primary antibody

New photoactive compound eradicates 'Iraqibacter' from wounds and skin infections

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

Lung in Oncology models for drug discovery launched by PRECOS

Fluxion Biosciences announces launch of Discovery Services business

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

AngioPredict project to focus on patients with metastatic colorectal cancer

ABL receives CE-IVD approval for DeepChek and ViroScore Suite clinical genotyping solutions

Cepheid’s Xpert CT/NG system receives European CE marking

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News